Key facts
- Lilly Asia Ventures is a venture capital firm based in Hong Kong, Hong Kong with 8 tracked portfolio companies.
- Notable positions include InSilico Medicine Cayman (HKG: 03696), Caidya, Avenzo Therapeutics, Akura Medical, Precede Biosciences.
- Lilly Asia Ventures has 1 fund on record, raising $100.0M across the 1 that report a size.
About Lilly Asia Ventures
Founded in 2008, Lilly Asia Ventures is a corporate venture capital arm of Eli Lilly headquartered in Hongkong. The firm prefers to invest in seed-stage, early-stage, and later-stage companies. The firm seeks to invest in healthcare, life sciences, manufacturing, the internet of things, oncology, and technology-based sectors in China and the United States.
Free account
See the whole book
- ·Watchlist + alerts for Lilly Asia Ventures's activity
Create free account
No card required
Portfolio, priced
8 companies · by our current valuations| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| InSilico Medicine Cayman (HKG: 03696) | Biotech | $1.7B | — | |
| Caidya | Other Healthcare Services | $1.0B | — | |
| Avenzo Therapeutics | — | $590.0M | — | |
| Akura Medical | — | $215.0M | — | |
| Precede Biosciences | — | $198.5M | — | |
| Khartis Therapeutics | — | $74.0M | — | |
| KSQ | — | — | — | |
| SciNeuro Pharmaceuticals | — | — | — |
Funds
1 recorded- Lilly Asia Ventures Fund III, L.P.2015$100.0M
$100.0M raised across the 1 fund that report a size
Frequently asked
- What companies does Lilly Asia Ventures invest in?
- Lilly Asia Ventures has 8 recorded portfolio companies, including InSilico Medicine Cayman (HKG: 03696), Caidya, Avenzo Therapeutics, Akura Medical.
- What is Lilly Asia Ventures's AUM?
- Lilly Asia Ventures manages approximately $5.6B in assets.